In Vitro and in Vivo Anti-Tumor Activity of Recombinant Mouse Tumor Necrosis Factor (TNF) in a Mouse Bladder Tumor (MBT-2)

No AccessJournal of Urology1 Jul 1990In Vitro and in Vivo Anti-Tumor Activity of Recombinant Mouse Tumor Necrosis Factor (TNF) in a Mouse Bladder Tumor (MBT-2) Robert R. Bahnson, and Timothy L. Ratliff Robert R. BahnsonRobert R. Bahnson Recipient of American Cancer Society Clinical Oncology Career Development Award 86-48. More articles by this author , and Timothy L. RatliffTimothy L. Ratliff More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)39404-1AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Tumor necrosis factor (TNF) has confirmed anti-tumor activity. When used in combination with interferon gamma (IFNG) or chemotherapeutic drugs targeted at DNA topoisomerase II, synergistic cytotoxicity has been observed. Investigations of the anti-tumor activity of recombinant mouse TNF in a mouse bladder tumor model (MBT-2) were performed. The cytotoxicity of TNF and low dose actinomycin-D (AMD) against MBT-2 in vitro was examined alone and following preincubation with IFNG. The activity of TNF/AMD in vivo utilizing an intravesical implantation mode (MBT-2) was also evaluated. TNF alone had no cytotoxic effect in vitro. TNF/AMD was cytotoxic for MBT-2 growth in vitro. Maximum cytotoxicity (86%) occurred at one μg./ml. TNF/one μg./ml. AMD with 50% cytotoxicity at .64 μg./ml. TNF/one/μg./ml. AMD. A two hour preincubation with IFNG markedly increased the cytotoxicity of TNF/AMD whereas longer incubations did not enhance cytotoxic activity. TNF alone and in combination with AMD did not significantly reduce the percentage of intravesical tumor outgrowth in vivo compared to controls. This study demonstrated that TNF/AMD exhibits cytotoxicity for MBT-2 cells in vitro but is ineffective in reducing implantation of intravesical tumors in vivo. The in vitro data suggest brief exposure of MBT-2 cells to IFNG augments the subsequent anti-tumor activity of TNF/AMD. © 1990 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited ByGlazier D, Bahnson R, McLeod D, von Roemeling R, Messing E and Ernstoff M (2018) Intravesical Recombinant Tumor Necrosis Factor in the Treatment of Superficial Bladder Cancer: An Eastern Cooperative Oncology Group StudyJournal of Urology, VOL. 154, NO. 1, (66-68), Online publication date: 1-Jul-1995.Van Moorselaar R, Hendriks B, Borm G, Van Der Meide P, Debruyne F and Schalken J (2018) Inhibition of Rat Bladder Tumor (Rbt323) Growth by Tumor Necrosis Factor Alpha and Interferon-Gamma in VivoJournal of Urology, VOL. 148, NO. 2 Part 1, (458-462), Online publication date: 1-Aug-1992. Volume 144Issue 1July 1990Page: 172-175 Advertisement Copyright & Permissions© 1990 by The American Urological Association Education and Research, Inc.MetricsAuthor Information Robert R. Bahnson Recipient of American Cancer Society Clinical Oncology Career Development Award 86-48. More articles by this author Timothy L. Ratliff More articles by this author Expand All Advertisement PDF DownloadLoading ...